التداخل المرتبط بين مركبات التوافق النسيجي والبروتين السرطاني بورز في خلايا سرطان الجلد

[1]-van der Bruggen,P., Traversari, C . , Chomez, P ., Lurquin, C ., De Plaen, E. , Van den Eynde, B ., Knuth, A and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643–1647.

[2]-Scanlan, M.J., Gure, A.O., Jungbluth, A.A., Old, L.Jand Chen, Y.T.(2002). Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.Immunol Rev,188, 22-32.

[3]-Scanlan,M.J., Simpson, A.J.G and Old, L.J. (2004). The cancer/testis genes: Review, standardization, and commentary.Cancer Immunity, 4, 1.

[4]-Boel, P., Wildmann, C., Sensi, M.L., Brasseur, R., Renauld, J.-C., Coulie, P., Boon, T and van der Bruggen, P.(1995). BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2, 167-175.

[5]-De Backer,O., Arden, K.C., Boretti, M., et al., (1999). Characterization of the GAGEGenes That Are Expressed in Various Human Cancers and in Normal Testis. Cancer Res, 59, 3157-3165.

[6]-Sugita,Y., Wada, H., Fujita, S., et al., (2004). NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. Cancer Res, 64, 2199-2204.

[7]-Jungbluth,A.A., Busam, K.J., Kolb, D, Iversen, K., Coplan, K., Chen, Y-T., Spagnoli, G.C and Old, L.J. (2000). Expression of mage-antigens in normal tissues and cancer. Int. J. Cancer,85,460–465.

[8]-Jones,T.A., Ogunkolade, B.W., Szary, J., Aarum, J., Mumin, M.A., Patel, S., Pieri, C.A and Sheer, D. (2011).Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells. PLoS ONE, 6, e22399.

[9]-Gnjatic,S., Nishikawa, H., Jungbluth, A.A., Güre, A.O., Ritter, G., Knuth, A., Chen, Y-T and Old, L.I. (2006). NY-ESO-1: Review of an immunogenic tumor antigen. Advances in Cancer Research, 95, 1-30.

[10]-Klenova,E.M., Morse, H.C., Ohlsson, R and Lobanenkov, V.V. (2002). The novel BORIS+ CTCF gene family is uniquely involvedin the epigenetics of normal biology and cancer. Seminars in cancer biology, 12, 399–414.

[11]-Risinger,J.I., Chandramouli, G.V.R ., Maxwell, G.L ., et al., (2007). Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression. Clin Cancer Res, 13, 1713-1719.

[12]-D'Arcy, V., Pore, N., Docquier, F., et al., (2008).BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.British Journal of Cancer, 98,571–579.

[13]-D'Arcy, V.,Abdullaev, Z.K.,Pore, N.,Docquier, F.,Torrano, V.,Chernukhin, I.,Smart, M.,Farrar, D.,Metodiev, M.,Fernandez N.,Richard, C.,Delgado, M.D.,Lobanenkov, V.,Klenova, E. (2006). The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 12, 5978-86.

[14]-Zhang, Y., Fang, M ., Song, Y.,Ren, J ., Fang, Jand Wang, X. ( 2017). Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer. Sci Rep. 7, 40786.

[15]-Benlalam,H., Linard, B., Guilloux, Y., Moreau-Aubry, A.,Derré, L., Diez,E., Dreno, B.,Jotereau, Fand Labarrière, N. (2003). Identification of Five New HLA-B*3501-Restricted Epitopes Derived from Common Melanoma-Associated Antigens, Spontaneously Recognized by Tumor-Infiltrating Lymphocytes. The Journal of Immunology, 171,6283-6289.

[16]-Chen,Q., Jackson, H., Parente, P., et al., (2004). Immunodominant CD4 responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. PNAS, 101, 9363-9368.

[17]-Jackson, H., Dimopoulos, N., Mifsud, N.A., et al., ( 2006). Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.J Immunol, 176, 5908-17.

[18]-Jäger,E., Chen,Y-T., Drijfhout,J.W., et al., (1998). Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes.J Exp Med., 187,265–270.

[19]-Jäger,E., Jäger,D, Karbach,J., et al., (2000). Identification of NY-ESO-1 Epitopes Presented by Human Histocompatibility Antigen (HLA)-DRB4*0101–0103 and Recognized by CD4+ T Lymphocytes of Patients with NY-ESO-1–expressing Melanoma.J Exp Med.,191,625–630.

[20]-Jäger, E., Karbach, J., Gnjatic, S., et al., (2002). Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun., 2, 12.

[21]-Gnjatic,S., Nagata, Y., Jäger, E., et al., (2000). Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. PNAS , 97,10917–10922.

[22]-Mandic,M., Castelli, F., Janjic, B., et al., (2005). One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol., 174, 1751-1759.

[23]-Wang, R-F., Johnston, S.L., Zeng, G., Topalian, S.L., Schwartzentruber, D.J and Rosenberg, S.A. (1998). A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames. J Immunol ,161 , 3596–3606.

[24]-Zarour, H.M., Maillere, B., Brusic, V., et al., (2002). NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res.62, 213-8.

[25]-Zeng, G., Touloukian, C.E., Wang, X., Restifo, N.P., Rosenberg, S.A and Wang, R-F. (2000). Identification of CD4+ TCell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules. J Immunol, 165, 1153–1159.

[26]-Zeng, G., Wang, X., Robbins, P.F., Rosenberg, S.A and Wang, R-F. (2001). CD4+ T cell recognition of MHC class II-restricted epitopesfrom NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-antibody production. PNAS, 98,3964–3969.

[27]-Loukinov, D., Ghochikyan, A., Mkrtichyan, M ., Ichim, T.E., Lobanenkov, V.V., Cribbs, D.H and Agadjanyan, M.G. (2006). Antitumor Efficacy of DNA Vaccination to the Epigenetically Acting Tumor Promoting Transcription Factor BORIS and CD80 Molecular Adjuvant. Journal of Cellular Biochemistry , 98, 1037–1043.

[28]-Ghochikyan, A., Mkrtichyan, M ., Loukinov, D ., Mamikonyan, G., Pack, S.D .,Movsesyan, N., Ichim, T.E., Cribbs, D.H., Lobanenkov, V.V and Agadjanyan, M.G. (2007). Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites. The Journal of Immunology, 178, 566 –573.

[29]-Mkrtichyan, M., Ghochikyan, A., Loukinov, D., Davtyan, H., Ichim, T.E., Cribbs, D.H., Lobanenkov, V.V and Agadjanyan, M.G. (2008). DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumour growth and prolongs the survival of mice. Gene Therapy ,15, 61–64.

[30]-Mkrtichyan,M., Ghochikyan, A., Davtyan, H., et al., (2011). Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol, 270, 188–97.

[31]-Hong,J.A., Kang, Y., Abdullaev, Z., et al.,(2005). Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer research , 65, 7763-74.

[32]-Vatolin,S., Abdullaev, Z., Pack, S.D., et al., (2005). Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer research, 65, 7751. AACR.

[33]-Kang, Y., Hong, J.A, Chen, G.A., et al., (2005). Modulation ofNY-ESO-1 expression in lung cancer cells by brother of the regulator of imprinted sites [abstract], Proc Amer Assoc Cancer Res (AACR), Abstract no. 36, 643